ArticlePharmacoEconomics2026

Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma.

Mirre Scholte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.